...Good afternoon, good evening, and thank you all for joining us. My name is Keyur Parekh. And hopefully, you can all hear me okay. Deborah, Kim, hopefully, you guys -- both of you can hear me okay. Brilliant. So thank you all for joining. As I said, my name is Keyur Parekh, and I cover GlaxoSmithKline for Goldman Sachs. I'm truly sorry, I'm not there in person this afternoon. But Deborah, Kim, thank you very much for joining us. So by way of introduction, Deborah is the CEO of ViiV, which is the HIV business for GlaxoSmithKline; and Kim is the Head of R&D kind of for ViiV. So Deborah, before we go into the Q&A session, just wondering if you want to kind of give us some important comments, your thoughts on how you see the landscape for HIV therapeutics, and then we'll go into some question and answers before we turn it over to the audience questions. But please kick us off. Deborah Jayne Waterhouse ...
